1-630-590-7762
SALEM, N.H., Nov. 18, 2015 /PRNewswire/ -- At this year's Radiological Society of North America (RSNA) annual meeting, Gamma Medica, Inc., a breast imaging medical device company, invites congress attendees to experience LumaGEM® - the latest in Molecular Breast Imaging (MBI) at Booth #1741 in South Hall A. The LumaGEM MBI system features dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology that identifies tumors as small as 5 mm in dense breast tissue where mammography findings are inconclusive or even negative.
The growing awareness of the limitations of mammography screening for women with dense breast tissue and the necessity for an effective adjunct screening technology led to the creation of LumaGEM MBI. Unlike mammography, tomosynthesis, ultrasound and MRI, all of which are anatomical imaging tests, MBI is a functional imaging modality that highlights metabolic activity in the breast and detects tumors not visible on a mammogram due to tissue density.
A recent study conducted by Mayo Clinic, and published in two articles in the American Journal of Roentgenology (AJR) in 2015, determined that the addition of MBI, such as the LumaGEM MBI system, to an annual mammogram screening demonstrated a near 400 percent increase in invasive breast cancer detection rates, 50 percent reduction in biopsies[i] and a subsequent 15 percent lower cost per cancer detected than screening with mammography alone.[ii] With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue and complicated mammograms with fewer false positives relative to anatomical imaging technologies making it an ideal supplemental screening tool. For more information about the secondary breast cancer screening process with MBI and workflow integration view our video with Dr. Robin Shermis, Medical Director of ProMedica Breast Care.
To learn more about MBI technology, please attend the following presentations during RSNA:
The LumaGEM MBI system is FDA approved and received its CE Mark allowing for the sale and distribution within the European Economic Area (EEA).
About Gamma Medica, Inc.
Gamma Medica, Inc. is a women's health company focused on overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. The company's LumaGEM® MBI system is the first commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. For more information visit www.gammamedica.com.
i Rhodes DJ, HruskaCB, ConnersAL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced RadiaFon Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251.
ii HruskaCB, ConnersAL, Jones KN, et al. DiagnosFc Workup and Costs of a Single Supplemental Molecular Breast Imaging Screen of Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(6):1345-1353. doi:10.2214/AJR.14.13306.
Logo - http://photos.prnewswire.com/prnh/20150814/258614LOGO
SOURCE Gamma Medica, Inc.